Pantoprazole sodium price December 2025 and outlook (see chart below)
- India:US$52.65/KG, -5.1% down
Business Analytiq assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness, or timeliness.
NEED A QUICK DOWNLOAD?
ACCESS TO OUR FULL DATABASE IS US$399/YEAR, WITH A 30-DAY $50 TRIAL
GET THAT DOWNLOAD IN 3 MINUTES!
BusinessAnalytiq provides a database of hundreds of market & price trend data, as well as online tools to set up benchmarks and leading indicators.
Pantoprazole sodium price index
This post is a summary of the Pantoprazole sodium price developments. The price developments of Pantoprazole sodium are expressed in US$ prices converted FX rates applicable at the time when the price was valid. Pantoprazole sodium price index developments are calculated from multiple separate sources of data to ensure statistical accuracy.
The outlook for Pantoprazole sodium prices is generated from different inputs including:
- Very recent price developments of immediate cost drivers of Pantoprazole sodium prices
- Recent price developments of underlying feedstocks which drive the price of Pantoprazole sodium
- Market futures for both cost drives and feedstocks of Pantoprazole sodium prices
- Adjustment of current supply/demand imbalances in the Pantoprazole sodium market
- Longer term trends in likely demand conditions
What is Pantoprazole sodium and what is it used for
Pantoprazole sodium is the sodium salt form of the proton pump inhibitor (PPI) pantoprazole. It works by inhibiting the H⁺/K⁺‑ATPase (the “proton pump”) in stomach parietal cells, thereby reducing gastric acid secretion. It is used to treat conditions caused by excess stomach acid, such as erosive esophagitis associated with Gastroesophageal reflux disease (GERD), to maintain healing of acid‑related esophageal damage, and to manage pathological hypersecretory conditions such as Zollinger‑Ellison syndrome. It may also be used to treat ulcers (e.g., from NSAIDs) and linked damage from acid reflux or stomach acid.
How is Pantoprazole sodium used
The medication is available in different formulations, including delayed‑release oral tablets (commonly 20 mg or 40 mg) and an injectable (intravenous) form in hospitalized patients unable to take oral medication. For adults with erosive esophagitis due to GERD, a typical regimen might be once daily for up to 8 weeks; in maintenance therapy the same dose (e.g., 40 mg once daily) may be continued under medical supervision. In children aged 5 years or older it is approved for short‑term healing of erosive esophagitis but long‑term safety has less evidence. Like other PPIs, it is recommended to take it before a meal (often 30–60 minutes before breakfast) for optimal effect. Patients must follow their prescribing physician’s instructions, and long‑term use may require monitoring for risks (e.g., low magnesium, vitamin B12 deficiency, fractures) associated with extended PPI therapy.
How large is the global market for Pantoprazole sodium and where is it produced
The global market for pantoprazole/pantoprazole sodium is sizeable and growing. One source estimates that the market size for all pantoprazole formulations was about **USD 2.51 billion in 2024**, with projections up to around USD 4.34 billion by 2034 (CAGR approx. 5.64 %). Another source more specifically for pantoprazole sodium reports the market at **USD 739.5 million in 2024**, projected to reach around USD 981.9 million by 2033 (CAGR about 3.2 %). Producing this product is a global enterprise: major active pharmaceutical ingredient (API) manufacturers are based in India (e.g., Dr. Reddy’s Laboratories), China, Spain and elsewhere. Finished dosage formulations are also produced worldwide by generic manufacturers. The supply chain of the API for pantoprazole sodium lists dozens of manufacturers/exporters, notably many in India. /p>